End Game: Adrenomed Targets Global Reach For Sepsis Candidate

German biotech Adrenomed has proof-of-concept data showing its sepsis drug can cut mortality by 67%. Now, it needs money to move the candidate into Phase IIb/III trials.  

Sepsis Indication
The Deadly And All-Too-Common Complication Has Defied Effective Treatments • Source: Shutterstock

More from Market Intelligence

More from In Vivo